http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2009533016-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5008 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4711 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 |
| filingDate | 2007-02-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2009-09-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2009533016-A |
| titleOfInvention | Presenilin 1 specific inhibitors and their use |
| abstract | The present invention provides a method of determining whether an agent preferentially inhibits presenilin 1 containing γ-secretase over presenilin 2 containing γ-secretase. The present invention also provides an agent that preferentially inhibits presenilin 1-containing γ-secretase over presenilin 2-containing γ-secretase, a pharmaceutical composition containing such a compound, and a method for treating Alzheimer's disease using such a compound. I will provide a. The present invention further discloses that the N-terminal domains of presenilin 1 and presenilin 2 establish differences in the production of Aβ by PS1-containing γ-secretase and PS2-containing γ-secretase. This discovery identified structural determinants for the differences observed in the production of Aβ by PS1-containing γ-secretase and PS2-containing γ-secretase. Such structural determinants have not been previously identified. The present invention also provides a method for determining whether an agent specifically binds to the N-terminus of PS1. The present invention further provides a method for treating Alzheimer's disease by administering an effective amount of an agent that specifically binds to PS1 and consequently inhibits the activity of PS1. |
| priorityDate | 2006-02-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 190.